← Back

Wire · opportunities

CraniUS Therapeutics Receives FDA 510(k) Clearance for the CraniUS® Plate, a Patient ...

Published

9 September 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at biospace.com

Verified

Fusion42 · 10 September 2026 · Fusion42 review

CraniUS Therapeutics has received FDA 510(k) clearance for its patient-specific CraniUS Plate, enabling the company to market its first product in the U.S. This implant serves as the foundation for the company's NeuroPASS platform aimed at advanced cranial implants with future capabilities like brain access, diagnostics, and drug delivery.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ The Wire takeaway

You have a new, FDA-cleared way to offer surgeons patient-specific cranial implants today while preparing to add diagnostics and drug delivery to the same platform. This clearance opens the door to capturing surgical market share before competitors develop similar advanced cranial implant features.

Coverage

1 source · 9 Sep 2026

Related on Wire

Topics

Medtechfda-clearancecranial-implantpatient-specificneurotechnologymedtechus-market